PE20020406A1 - 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES - Google Patents

7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES

Info

Publication number
PE20020406A1
PE20020406A1 PE2001000860A PE2001000860A PE20020406A1 PE 20020406 A1 PE20020406 A1 PE 20020406A1 PE 2001000860 A PE2001000860 A PE 2001000860A PE 2001000860 A PE2001000860 A PE 2001000860A PE 20020406 A1 PE20020406 A1 PE 20020406A1
Authority
PE
Peru
Prior art keywords
disustituted
pyrido
pyrimidines
oxo
inhibitors
Prior art date
Application number
PE2001000860A
Other languages
Spanish (es)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Julie Anne Lim
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020406A1 publication Critical patent/PE20020406A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6 DISUSTITUIDAS DE FORMULA I DONDE R1 ES H, ALQUILO; R2 ES CICLOALQUILO, CICLOALQUILO HETEROSUSTITUIDO, ARALCOXI, ALCOXI, HETEROCICLICLO, ENTRE OTROS; R3 ES H, AMINO, MONOALQUILOAMINO, DIALQUILAMINO, ACILAMINO, ALQUILO, CICLOLAQUILO, -NRa-C(=O)-Rb, ENTRE OTROS DONDE Ra ES H, ALQUILO; Rb ES HETEROCICLILO, HETEROALQUILO; AR1 Y AR2 SON ARILO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA II DONDE AR1 ES FENILO. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS PROTEINA CINASAS Y SON UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDAD DE CROHN, ALZHEIMERREFERS TO 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6 DISUSTITUTED OF FORMULA I WHERE R1 IS H, ALKYL; R2 IS CYCLOALKYL, HETEROSUSTITUTED CYCLOALKYL, ARALCOXI, ALCOXI, HETERO CYCLE, AMONG OTHERS; R3 IS H, AMINO, MONOALKYLAMINE, DIALKYLAMINE, ACILAMINE, ALKYL, CYCLOLAKYL, -NRa-C (= O) -Rb, AMONG OTHERS WHERE Ra IS H, ALKYL; Rb IS HETEROCYCLYL, HETEROALKYL; AR1 AND AR2 ARE ARYL. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE PREFERRED COMPOUNDS ARE THE COMPOUNDS OF FORMULA II WHERE AR1 IS PHENYL. THE MENTIONED COMPOUNDS ARE INHIBITORS OF PROTEIN KINASES AND ARE USEFUL FOR THE TREATMENT OF ARTHRITIS, CROHN'S DISEASE, ALZHEIMER

PE2001000860A 2000-08-31 2001-08-28 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES PE20020406A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22958400P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
PE20020406A1 true PE20020406A1 (en) 2002-05-17

Family

ID=22861859

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000860A PE20020406A1 (en) 2000-08-31 2001-08-28 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES

Country Status (15)

Country Link
EP (1) EP1315726A1 (en)
JP (1) JP4141830B2 (en)
KR (1) KR100571339B1 (en)
CN (1) CN1275964C (en)
AR (1) AR033681A1 (en)
AU (2) AU9378401A (en)
BR (1) BR0113628A (en)
CA (1) CA2420286A1 (en)
GT (1) GT200100191A (en)
MX (1) MXPA03001821A (en)
PA (1) PA8527301A1 (en)
PE (1) PE20020406A1 (en)
UY (1) UY26918A1 (en)
WO (1) WO2002018380A1 (en)
ZA (1) ZA200301079B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
WO2002018379A2 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
CA2479644A1 (en) * 2002-04-03 2003-10-09 F. Hoffmann-La Roche Ag Imidazo fused compounds
AU2003225072A1 (en) * 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CA2506565A1 (en) 2002-11-18 2004-06-03 F. Hoffmann-La Roche Ag Diazinopyrimidines
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (en) 2003-04-10 2005-12-12 Hoffmann La Roche Pyrimido compounds.
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
CN100455582C (en) * 2003-11-13 2009-01-28 霍夫曼-拉罗奇有限公司 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
WO2006082492A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US20090221600A1 (en) * 2005-09-28 2009-09-03 Ashwani Kumar Verma Pyrido-pyridimidine derivatives useful as antiinflammatory agents
ATE439361T1 (en) 2006-01-31 2009-08-15 Hoffmann La Roche 7H-PYRIDOÄ3,4-DÜPYRIMIDINE-8-ONE, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE INHIBITORS
KR100661523B1 (en) * 2006-06-09 2006-12-26 주식회사 청용산기 Box correcting device of stitching progress for carton box erecting
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010509265A (en) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods of use thereof
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
KR101106162B1 (en) * 2010-04-20 2012-01-20 주식회사 청용산기 Stitching device for packing box making apparatus
EA031267B1 (en) * 2012-03-22 2018-12-28 Оскотек, Инк. Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
AR101813A1 (en) 2014-09-12 2017-01-11 Biolab Sanus Farmacêutica Ltda COMPOUNDS DERIVED FROM PYRIDOPIRIMIDINES
HRP20221196T1 (en) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2022517189A (en) 2019-01-03 2022-03-07 ジェネンテック， インコーポレイテッド Pyrido-pyrimidinone compounds and pteridinone compounds as inhibitors of the inositol-requiring enzyme I (IREIalpha) of endoribonucleases for the treatment of cancer diseases
CA3142340A1 (en) * 2019-05-31 2020-12-03 Les Laboratoires Servier Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2022052924A1 (en) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 Preparation method for class of nitrogen-containing fused ring compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1085666C (en) * 1994-11-14 2002-05-29 沃尼尔·朗伯公司 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyrosine kinase medicated cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DE69939168D1 (en) * 1998-05-26 2008-09-04 Warner Lambert Co BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELL REPRODUCTION

Also Published As

Publication number Publication date
AU2001293784B2 (en) 2007-08-30
UY26918A1 (en) 2002-02-28
EP1315726A1 (en) 2003-06-04
WO2002018380A1 (en) 2002-03-07
PA8527301A1 (en) 2002-07-30
CN1275964C (en) 2006-09-20
JP2004507541A (en) 2004-03-11
CN1451005A (en) 2003-10-22
AR033681A1 (en) 2004-01-07
CA2420286A1 (en) 2002-03-07
KR20030022422A (en) 2003-03-15
JP4141830B2 (en) 2008-08-27
KR100571339B1 (en) 2006-04-17
AU9378401A (en) 2002-03-13
BR0113628A (en) 2003-07-01
ZA200301079B (en) 2004-05-07
GT200100191A (en) 2002-05-16
MXPA03001821A (en) 2003-06-04

Similar Documents

Publication Publication Date Title
PE20020406A1 (en) 7-OXO-PYRIDO [2,3-d] PYRIMIDINES 2,6-DISUSTITUTED AS INHIBITORS OF PROTEIN KINASES
PE20120814A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
EA200501333A1 (en) 5,7-DIAMINOPYRAZOLO [4,3-d] Pyrimidines, useful in the treatment of hypertension
PE20010211A1 (en) THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEIN KINASES
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
EA200500342A1 (en) HETEROCYCLIC SUBSTITUTED PIPERASINES FOR THE TREATMENT OF SCHIZOPHRENIA
EA200100971A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS
AR045595A1 (en) USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS
PE20030129A1 (en) IMIDAZOTRIAZINES
PE20130012A1 (en) PIRAZOLE DERIVATIVES AS JAK INHIBITORS
EA200200716A1 (en) ARYL CONDENSED AZOPOLYCYCLIC COMPOUNDS
UY26872A1 (en) DERIVATIVES OF THE 4- PIRIDINE PHENYL
ECSP034744A (en) N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS
EA200200337A1 (en) DERIVATIVES OF PYRAZOLO [4,3-d] PYRIMIDINE
ATE469892T1 (en) SUBSTITUTED 1H-DIHYDROPYRAZOLES, THEIR PREPARATION AND USE
ECSP045229A (en) PIRIDINONES REPLACED AS MODULATORS OF THE P38 MAP QUINASA
AR051735A1 (en) PIRROLIC INHIBITORS OF THE PROTEIN QUINASA ERK, SYNTHESIS AND INTERMEDIARIES OF THE SAME.
BR0008056A (en) Substituted fused pyrrolocarbazoles and cyclic isoindolones
BG66085B1 (en) Phenylalanine derivatives
EA200600973A1 (en) PYRIDO [2,3-d] PYRIMIDIN-2,4-DIAMINS AS PDE 2 INHIBITORS
PE20011066A1 (en) PYRID [2,3-d] PYRIMIDIN-2,7-DIAMINES KINE INHIBITORS
PE20060355A1 (en) I HAVE [3,2-b] PYRIDIN-6-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE
AR054508A1 (en) BENCILPIPERAZINE COMPOSITE, ITS USE TO PREPARE A MEDICINAL PRODUCT, PROCEDURES FOR THE PREPARATION OF SUCH COMPOUND AND INTERMEDIATE COMPOUNDS, SUCH INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE IT
EA200600605A1 (en) REJUVENATED PENTANOLS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-INFLAMMATORY MEANS

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed